CLAIMS

1. Use of bupropion in the manufacture of a medicament for increasing dextromethorphan plasma levels in a human being who is an extensive metabolizer of dextromethorphan and is in need of treatment with dextromethorphan, wherein the medicament is to be co-administered with dextromethorphan to the human being for at least eight consecutive days, and wherein, on the eighth day that the medicament is to be co-administered with dextromethorphan, the AUC_{0-12} of dextromethorphan is at least 400 ng·hr/mL.

2. The use of claim 1, wherein on the eighth day that the medicament is to be co-administered with dextromethorphan, the C_{max} of dextromethorphan is at least 40 ng/mL.

3. The use of claim 1 or 2, wherein on the eighth day that the medicament is to be co-administered with dextromethorphan, the AUC_{0-12} of dextromethorphan is at least 600 ng·hr/mL.

4. The use of any one of claims 1 to 3, wherein 40 mg to 140 mg of dextromethorphan is to be administered per day.

5. The use of claim 4, wherein 60 mg to 100 mg of dextromethorphan is to be administered per day.

6. The use of any one of claims 1 to 5, wherein 100 mg to 250 mg of bupropion is to be administered per day.

7. The use of any one of claims 1 to 5, wherein 200 mg to 250 mg of bupropion is to be administered per day.

8. The use of any one of claims 1 to 7, wherein bupropion is to be co-administered in an amount that results in a plasma concentration of dextromethorphan in the human being on the eighth day that is at least 10 times the plasma concentration on the eighth day of the same amount of dextromethorphan to be administered without bupropion for eight consecutive days.

9. The use of any one of claims 1 to 8, wherein the medicament is to be co-administered with dextromethorphan for the treatment of pain or a neurological disorder.

10. The use of claim 9, wherein the pain comprises postoperative pain, cancer pain, arthritic pain, lumbosacral pain, musculoskeletal pain, central multiple sclerosis pain, nociceptive pain, or neuropathic pain.

11. The use of claim 9, wherein the neurological disorder is an affective disorder, a psychiatric disorder, a cerebral function disorder, a movement disorder, a dementia, a motor neuron disease, a neurodegenerative disease, a seizure disorder, or a headache.

12. The use of claim 9, wherein the neurological disorder is depression.

13. The use of claim 9, wherein the neurological disorder is agitation in Alzheimer's disease.

14. The use of any one of claims 1 to 13, wherein bupropion is to be co-administered with dextromethorphan in a single dosage form.

15. The use of any one of claims 1 to 14, wherein bupropion has an excess of one stereoisomer of bupropion.